Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report)'s share price was up 0.5% during mid-day trading on Wednesday . The stock traded as high as $3.08 and last traded at $2.99. Approximately 16,532 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 50,162 shares. The stock had previously closed at $2.97.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Alpha Tau Medical in a report on Tuesday, April 29th.
View Our Latest Research Report on Alpha Tau Medical
Alpha Tau Medical Stock Down 1.3%
The company's fifty day moving average is $2.89 and its 200-day moving average is $2.99. The company has a market capitalization of $252.76 million, a PE ratio of -6.48 and a beta of 0.99. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.81 and a current ratio of 5.81.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings data on Monday, May 19th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. As a group, analysts predict that Alpha Tau Medical Ltd. will post -0.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Alpha Tau Medical
Institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp grew its holdings in Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock valued at $151,000 after buying an additional 25,770 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after buying an additional 26,800 shares in the last quarter. Levin Capital Strategies L.P. grew its holdings in Alpha Tau Medical by 2.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock valued at $975,000 after buying an additional 7,189 shares in the last quarter. Kovitz Investment Group Partners LLC grew its holdings in Alpha Tau Medical by 601.4% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company's stock valued at $568,000 after buying an additional 194,055 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Alpha Tau Medical during the 1st quarter valued at approximately $53,000. 2.65% of the stock is owned by hedge funds and other institutional investors.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Further Reading
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
